All News
Bridgehead Pharmaceutical and Medical Device Consulting in Japan
Bridgehead International社は、製薬、バイオテクノロジー、医療機器、診断及び金融関連顧客から推奨される戦略 的コンサルタントパートナーである。同社は、世界的に事業展開しており、価格設定、費用償還、医療経済研究及 び市場参入支援、新規株式公開のためのデュー・デリジェンス及び査定サービス、ライセンス及びM&A、機会評価 及びトレーニングサービスを提供している。The pharmaceutial and medical device consulting services of Bridgehead International are featured in the quarterly bulletin published by the British Embassy in Tokyo, Japan.
Published: Tuesday, 1 June, 2010
Improved Cervical Cancer Screening Without Reimbursement Challenges
Cervical cancer screening using both an FDA-approved HPV DNA test plus a Pap test (co-testing) is supported by major clinical practice guidelines, but some clinicians may have concerns about implementing this process in their practices. Will patients still come back for their annual examination if they don’t need to be tested yearly? Will reimbursement be a problem? Bridgehead and Dr Karen Ilka report on the findings of a recent survey.
Published: Tuesday, 13 April, 2010
Personalised Medicine - Bridgehead International Enhances its Services
Personalised Medicine - Bridgehead International Enhances its Services. Natalie A. Cummins, of DHC Consulting will be joining Bridgehead International as an Affiliate. Bridgehead’s services will be expanded to offer payer expertise in the area of personalized medicine, including marketplace assessments, product coverage determinations and reimbursement strategy. In addition, the affiliation strengthens Bridgehead’s existing expertise in the diagnostic market access space, based on Ms. Cummins’ experience at Quest Diagnostics, working with converging technologies, and conducting strategic planning for diagnostic companies.
Published: Wednesday, 20 January, 2010
Integrating Pharma R&D and Supply Chain Issues with Commerical Strategy
Integrating Pharma R&D and Supply Chain Issues with Commerical Strategy. Bridgehead is pleased to announce that David Alderson has joined its UK team as Principal Consultant. David has pharmaceutical marketing, commercial and supply chain experience, gained over 17 years in both the Pharma and Biotech sectors. Much of his career has focused on integrating research, development and supply chain issues with commercial strategy. He has experience of a broad range of therapy areas, including pain, respiratory, inflammation, and infectious diseases.
Published: Friday, 23 October, 2009
Commercialisation of Biomedical Technologies - New Member of London Team
Commercialisation of Biomedical Technologies - New Member of London Team. As part of the on-going expansion of Bridgehead's European office, Roy Koruth has joined the London team as a Senior Consultant. Roy brings a wealth of experience across the biopharmaceutical/biotechnology space, gained as an independent healthcare consultant, following time spent as a Senior Executive at Imperial Innovations Ltd, where he was responsible for commercialising biomedical technologies. In this role Roy was responsible for sourcing, negotiating and executing licensing transactions with global partner
Published: Wednesday, 7 October, 2009
Bridgehead International Voted Strategic Advisor of the Year - Healthcare
Bridgehead International is pleased to announce that it has been voted UK Strategic Advisor of the Year – Healthcare in the ACQ Finance Magazine Awards for 2009.
Published: Saturday, 4 July, 2009
Bridgehead Establishes Collaboration in Turkey
As part of its development of a global service in Market Access/Pricing and Reimbursement, Bridgehead is pleased to announce a collaboration agreement with two leading advisors on the Turkish market.
Published: Saturday, 4 April, 2009
Healthcare Reforms Revisited
Members of Bridgehead’s US Market Access team will be attending the International ISPOR (International Society for Pharmacoeconomic Research) congress May 16th to 20th, Orlando, Florida, USA.
Published: Saturday, 4 April, 2009
Jim Furniss, Speaking in Moscow
Jim Furniss has been invited by the Russian Ministry of Health and Social Development and the LEFF Group to speak at a conference on “Innovative Drugs Pricing for Socially Significant Diseases” on the subject of “Innovational pricing schemes for targeted therapy drugs.”
Published: Saturday, 4 April, 2009
Workshop and Presentations, Pharma Pricing and Market Access Outlook Europe
The Bridgehead Market Access team will be in London from April 28th to May 1st at the Pharma Pricing and Market Access Outlook Europe 2009 Congress.
Published: Saturday, 4 April, 2009
Bridgehead Presents on Development of Value Based Pricing and Risk-sharing
The Bridgehead Market Access team will be in Brussels on April 23rd to 24th at the Pharmaceutical & Medical Device Risk-Sharing & Value-Based Pricing & Reimbursement Schemes, Congress.
Published: Saturday, 4 April, 2009
Patient Registry Strategies: A New Service from Bridgehead
Bridgehead International is pleased to announce an affiliation with Jeffrey P. Trotter, of J Trotter Research and Consulting.
Published: Wednesday, 4 March, 2009
